The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Key highlights in amyloidosis from ASH 2020
Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, shares her highlights in amyloidosis from ASH 2020. In particular, Dr Sanchorawala discusses the advances made in the ANDROMEDA trial, which demonstrated high hematological response rates, organ response rates and improvements in major organ deterioration and progression-free survival in newly diagnosed patients with immunoglobin light chain (AL) amyloidosis. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
